July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Updated incidence rates of legal blindness from age-related macular degeneration in Denmark: 2010-2016
Author Affiliations & Notes
  • Michael Larsen
    Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark
    Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Sara Brandi
    Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark
  • Inger Christine Munch
    Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark
    Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Footnotes
    Commercial Relationships   Michael Larsen, AbbVie (F), Allergan (F), Astrazeneca (F), Bayer (F), Novartis (F), Novo Nordisk (F); Sara Brandi, None; Inger Christine Munch, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 71. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Larsen, Sara Brandi, Inger Christine Munch; Updated incidence rates of legal blindness from age-related macular degeneration in Denmark: 2010-2016. Invest. Ophthalmol. Vis. Sci. 2019;60(9):71.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark in the period from 2010 to 2016 in the population aged 50 years and older.

Methods : Population-based observational registry study using the membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. Incident cases of legal blindness were tabulated for the population of citizens aged ≥50 years, which is where blindness from AMD occurs. The entire population in Denmark has free access to a single-payer public health care system. The main outcome measure was the change in the incidence rate of legal blindness from AMD from 2010 to 2016.

Results : The incidence rate of legal blindness attributable to AMD in citizens aged 50 years or older decreased from 25.7 cases per year per 100 000 in 2010 to 15.9 cases per year per 100 000 in 2016, corresponding to a reduction of 38 % (P < .0001, adjusted for age). The incidence of legal blindness from causes other than AMD was 10.6 cases per year per 100 000 in 2010 and 9.6 cases per year per 100 000 in 2016 and fluctuated around this level throughout the period of observation.

Conclusions : Legal blindness from AMD continued the decline observed between 2000 and 2010, where the incidence rate fell to 50 % of the year 2000 baseline. Thus, an additional decrease of 20 %, again compared to the year 2000 baseline, was seen from 2010 to 2016. This observation supports that ongoing efforts to prevent blindness from AMD have been effective. A cost-effectiveness analysis was not included in this study. No information was available about the incidence of visual impairment milder than legal blindness. The stagnating decline in blindness from causes other than AMD should prompt further analysis.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×